|Bid||79.43 x 900|
|Ask||79.44 x 900|
|Day's range||78.90 - 80.02|
|52-week range||65.25 - 92.64|
|Beta (5Y monthly)||0.49|
|PE ratio (TTM)||20.21|
|Forward dividend & yield||2.44 (3.10%)|
|1y target est||93.00|
Merck Announces New Safety and Efficacy Data for Investigational Islatravir in Combination with Doravirine in Adults with HIV-1 Infection
Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Merck Animal Health Completes Acquisition of U.S. Rights to SENTINEL® Brand of Combination Parasiticides for Companion Animals
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
FDA approves Merck's (MRK) Keytruda for first-line treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer.
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for First-Line Treatment of Patients With Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer
FDA Approves Merck’s KEYTRUDA® for the Treatment of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC).
Merck Underscores Commitment to HIV with New Data Analyses to be Presented at AIDS 2020: Virtual
Merck's (MRK) development program on V114 comprises 16 studies, evaluating safety, tolerability and immunogenicity of V114 in a variety of patient populations.
V114, Merck's Investigational 15-valent Pneumococcal Conjugate Vaccine, Met Safety and Immunogenicity Objectives in Initial Phase 3 Studies in Adults.
KEYTRUDA® Approved in China for Second-Line Treatment of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Merck's (MRK) sBLA seeking approval of Keytruda for advanced solid tumors, based on biomarker, regardless of tumor type, gets FDA's accelerated approval.
Merck's (MRK) type 2 diabetes drug, Steglatro, achieves primary endpoint of non-inferiority in major adverse CV events compared to placebo in a late-stage cardiovascular outcomes study.
FDA Approves Second Biomarker-Based Indication for Merck’s KEYTRUDA (pembrolizumab), Regardless of Tumor Type
Merck and Pfizer’s SGLT2 Inhibitor STEGLATRO Meets Primary Endpoint in VERTIS CV Trial for Patients with Type2 Diabetes and Atherosclerotic CV Disease
FDA grants accelerated approval for label expansion application of Merck's (MRK) human papillomavirus vaccine, Gardasil, to include oropharyngeal and other head and neck cancers.
Merck Announces Call for Proposals for Second Cohort of Safer Childbirth Cities, Expanding Maternal Health Support Across US Cities
Investors shouldn't settle for just an average dividend stock, certainly not during the COVID-19 pandemic when many dividend stocks are proving to be unstable. Instead, investors should look for great dividend stocks -- ones that offer sustainable payouts that are also safe, pay a good yield, and are likely to increase in the future. Today, I'll look at whether drug manufacturer Merck (NYSE: MRK) falls into the category of a great dividend stock and whether income investors should consider adding it to their portfolios.